0001567619-23-001396.txt : 20230127
0001567619-23-001396.hdr.sgml : 20230127
20230127213500
ACCESSION NUMBER: 0001567619-23-001396
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230125
FILED AS OF DATE: 20230127
DATE AS OF CHANGE: 20230127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ajer Jeffrey Robert
CENTRAL INDEX KEY: 0001557533
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26727
FILM NUMBER: 23565028
MAIL ADDRESS:
STREET 1: C/O BIOMARIN PHARMACEUTICAL INC.
STREET 2: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC
CENTRAL INDEX KEY: 0001048477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 680397820
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 4155066700
MAIL ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc1.xml
FORM 4
X0306
4
2023-01-25
0
0001048477
BIOMARIN PHARMACEUTICAL INC
BMRN
0001557533
Ajer Jeffrey Robert
C/O BIOMARIN PHARMACEUTICAL INC.
105 DIGITAL DRIVE
NOVATO
CA
94949
0
1
0
0
EVP, Chief Commercial Officer
Common Stock
2023-01-25
4
M
0
49000
67.81
A
90088
D
Common Stock
2023-01-25
4
S
0
44825
115.654
D
45263
D
Common Stock
2023-01-25
4
S
0
4175
116.1540
D
41088
D
Stock Option (Right to buy Common Stock)
67.81
2023-01-25
4
M
0
2200
0
D
2013-11-15
2023-05-14
Common Stock
2200
0
D
Stock Option (Right to buy Common Stock)
67.81
2023-01-25
4
M
0
46800
0
D
2013-11-15
2023-05-14
Common Stock
46800
0
D
Trade made pursuant to a 10b5-1 plan executed on February 28, 2022.
The price in column 4 is the weighted average price. The price actually received ranged from $115.000 to 115.998. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
The price in column 4 is the weighted average price. The price actually received ranged from $116.000 to $116.485. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Reflects the number of options outstanding after the transactions from this specific stock option grant.
/s/ Eric Fleekop, Attorney-in-Fact
2023-01-27